138 related articles for article (PubMed ID: 15774740)
1. Drug discovery. Magnificent obsession.
Couzin J
Science; 2005 Mar; 307(5716):1712-5. PubMed ID: 15774740
[No Abstract] [Full Text] [Related]
2. Tysabri risk causing headache for companies.
Sheridan C
Nat Rev Drug Discov; 2005 Sep; 4(9):703-4. PubMed ID: 16178114
[No Abstract] [Full Text] [Related]
3. [CD 40 L blockade as a novel treatment for chronic ITP refractory to corticosteroids and splenectomy].
Kuwana M
Rinsho Ketsueki; 2003 Feb; 44(2):82-9. PubMed ID: 12692980
[No Abstract] [Full Text] [Related]
4. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse.
Nanji SA; Hancock WW; Luo B; Schur CD; Pawlick RL; Zhu LF; Anderson CC; Shapiro AM
Diabetes; 2006 Jan; 55(1):27-33. PubMed ID: 16380473
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis poses tough drug development challenges.
Senior K
Drug Discov Today; 2005 Dec; 10(23-24):1583-4. PubMed ID: 16376813
[No Abstract] [Full Text] [Related]
6. Immunotherapeutic approaches with monoclonal antibodies to immunological diseases.
Cozzi E; Ferrone S
Recenti Prog Med; 1992 Sep; 83(9):528-33. PubMed ID: 1439123
[TBL] [Abstract][Full Text] [Related]
7. London's disastrous drug trial has serious side effects for research.
Wadman M
Nature; 2006 Mar; 440(7083):388-9. PubMed ID: 16554763
[No Abstract] [Full Text] [Related]
8. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
9. Fontolizumab Protein Design Labs.
Dumont FJ
Curr Opin Investig Drugs; 2005 May; 6(5):537-44. PubMed ID: 15912969
[TBL] [Abstract][Full Text] [Related]
10. Putting tolerance to the test.
Couzin J
Science; 2004 Jul; 305(5681):194-6. PubMed ID: 15247467
[No Abstract] [Full Text] [Related]
11. BX-471 Berlex.
Elices MJ
Curr Opin Investig Drugs; 2002 Jun; 3(6):865-9. PubMed ID: 12137405
[TBL] [Abstract][Full Text] [Related]
12. [Update: treatment of multiple sclerosis].
Kümpfel T; Hohlfeld R
MMW Fortschr Med; 2009 Mar; 151(13):70-2. PubMed ID: 19504824
[No Abstract] [Full Text] [Related]
13. Natalizumab (Tysabri) returns.
Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
[No Abstract] [Full Text] [Related]
14. Lack of descriptive support results in no interference-in-fact.
Nat Rev Drug Discov; 2004 Mar; 3(3):196. PubMed ID: 15046039
[No Abstract] [Full Text] [Related]
15. Fast track to MS drug.
Sheridan C
Nat Biotechnol; 2004 Aug; 22(8):939-41. PubMed ID: 15286635
[No Abstract] [Full Text] [Related]
16. Challenges and opportunities: what we are learning from the clinical natalizumab experience.
Kachuck NJ
Expert Rev Neurother; 2005 Sep; 5(5):605-15. PubMed ID: 16162084
[TBL] [Abstract][Full Text] [Related]
17. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
Ding C; Xu J; Li J
Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
[TBL] [Abstract][Full Text] [Related]
18. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis.
Achiron A; Miron S; Shoenfeld Y
Isr Med Assoc J; 2005 May; 7(5):283-5. PubMed ID: 15909458
[No Abstract] [Full Text] [Related]
19. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
Guillonneau C; Aubry V; Renaudin K; Séveno C; Usal C; Tezuka K; Anegon I
Transplantation; 2005 Aug; 80(4):546-54. PubMed ID: 16220623
[TBL] [Abstract][Full Text] [Related]
20. TRX-4 (TolerRx Inc).
Brown WM
IDrugs; 2006 Apr; 9(4):283-91. PubMed ID: 16596483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
